Pro-Dex, Inc. Announces Fiscal 2023 Second Quarter and Six-Month Results

Rhea-AI Summary

Pro-Dex, Inc. (NasdaqCM:PDEX) reported its fiscal 2023 second-quarter financial results for the period ended December 31, 2022. Net sales rose by $1.1 million (11%) to $11.3 million, driven by increased sales and repair revenue from orthopedic surgical handpieces. However, gross profit decreased by $781,000 (23%) to $2.6 million due to rising component costs and higher repair expenses. Operating expenses decreased by $316,000 (18%) to $1.5 million. Net income for the quarter was $879,000 ($0.24 per diluted share), a slight drop from $925,000 ($0.25 per diluted share) in the previous year. The company anticipates growth as operations commence at its new facility.

Positive

• Net sales increased by $1.1 million (11%) to $11.3 million.
• Operating expenses decreased by $316,000 (18%) to $1.5 million.
• Net income was $879,000, only a slight decline from the previous year.

Negative

• Gross profit decreased by $781,000 (23%) to $2.6 million.
• Six-month gross profit down by $1.3 million (18%) due to rising repair and component costs.

IRVINE, CA / ACCESSWIRE / February 2, 2023 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2023 second quarter ended December 31, 2022. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2023 with the Securities and Exchange Commission today.

Quarter Ended December 31, 2022

Net sales for the three months ended December 31, 2022 increased $1.1 million, or 11%, to $11.3 million from $10.2 million for the three months ended December 31, 2021, due primarily to sales of the orthopedic surgical handpiece that we sell to our largest customer coupled with increased repair revenue of that same handpiece.

Gross profit for the three months ended December 31, 2022 decreased $781,000, or 23%, to $2.6 million from $3.4 million for the same period in fiscal 2022, due to continuing price increases for components, especially chips for our printed circuit board assemblies, as well higher repair costs for the surgical handpiece that we sell to our largest customer. As previously disclosed, beginning in fiscal 2023 and continuing through the end of the second quarter of fiscal 2023, we began implementing a customer upgrade request for our largest customer. We have proceeded in good faith to upgrade all units returned for repair to the newest release of the handpiece while we continue to negotiate with this customer to obtain additional compensation for these more costly upgraded repairs.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended December 31, 2022 decreased $316,000, or 18%, to $1.5 million compared to $1.8 million in the prior fiscal year's corresponding quarter, reflecting in part the higher number of billable engineering projects in the current fiscal quarter compared to the same period in the prior fiscal year and reduced general and administrative expenses mostly due to declining non-cash stock compensation expense.

Net income for the quarter ended December 31, 2022 was $879,000, or $0.24 per diluted share, compared to $925,000, or $0.25 per diluted share, for the corresponding quarter in fiscal 2022.

Six Months Ended December 31, 2022

Net sales for the six months ended December 31, 2022 increased $2.2 million, or 11%, to $22.4 million from $20.2 million for the six months ended December 31, 2021, due primarily to increased repair revenue from the orthopedic surgical handpiece that we sell to our largest customer and increased non-recurring engineering and proto-type revenue.

Gross profitfor the six months ended December 31, 2022decreased $1.3 million, or 18%, compared to the same period in fiscal 2022 due to the increased costs incurred in the repairs of the surgical handpiece we sell to our largest customer as described above, continuing component price increases, and higher cost structures in our machine shop, assembly, materials, and quality departments.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the six months ended December 31, 2022 decreased $420,000, or 11%, to $3.5 million compared to $3.9 million in the prior fiscal year's corresponding period.

Net income for the six months ended December 31, 2022 and 2021 remained flat at $2.0 million, or $0.53 per diluted share.

CEO Comments

Richard L. ("Rick") Van Kirk, the Company's President and Chief Executive Officer, commented, "We are pleased with our second quarter and year-to-date results especially considering the challenging environment facing businesses today." Mr. Van Kirk continued, "We are excited to begin operations in the Franklin facility this fiscal quarter and we remain positive that the building will allow for our continued expected growth."

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex, Inc. also sells rotary air motors to a wide range of industries. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance (including, but not limited to, the anticipated commencement of operations in the Franklin facility and expected future growth), as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)

PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share amounts)

		December 31, 2022				June 30, 2022
ASSETS
Current assets:
Cash and cash equivalents		$	382			$	849
Investments			1,134				755
Accounts receivable, net of allowance for doubtful accounts of $2 and $0 at December 31, 2022 and at June 30, 2022, respectively			12,195				15,384
Deferred costs			877				710
Inventory			15,135				12,678
Prepaid expenses and other current assets			1,664				790
Total current assets			31,387				31,166
Land and building, net			6,296				6,343
Equipment and leasehold improvements, net.			5,203				4,833
Right-of-use asset, net			2,063				2,248
Intangibles, net			98				118
Deferred income taxes, net			764				797
Investments			1,726				1,779
Other assets			42				42
Total assets		$	47,579			$	47,326
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	3,364			$	3,761
Accrued expenses			3,314				2,751
Income taxes payable			1,026				544
Deferred revenue			851				1,013
Notes payable			3,110				3,285
Total current liabilities			11,665				11,354
Lease liability, net of current portion			1,850				2,054
Notes payable, net of current portion			9,590				10,250
Total non-current liabilities			11,440				12,304
Total liabilities			23,105				23,658
Shareholders' equity:
Common shares; no par value; 50,000,000 shares authorized; 3,553,929 and 3,596,131 shares issued and outstanding at December 31, 2022 and June 30, 2022, respectively			6,533				7,682
Retained earnings			17,941				15,986
Total shareholders' equity			24,474				23,668
Total liabilities and shareholders' equity		$	47,579			$	47,326

PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)

		Three Months Ended December 31,								Six Months Ended December 31,
		2022				2021				2022				2021
Net sales		$	11,282			$	10,173			$	22,369			$	20,161
Cost of sales			8,659				6,769				16,791				13,329
Gross profit			2,623				3,404				5,578				6,832
Operating expenses: Selling expenses			68				22				122				59
General and administrative expenses			951				1,165				1,975				2,257
Research and development costs			467				615				1,395				1,596
Total operating expenses			1,486				1,802				3,492				3,912
Operating income			1,137				1,602				2,086				2,920
Interest expense			(128	)			(117	)			(258	)			(237	)
Unrealized gain (loss) on marketable equity investments			158				(300	)			408				(152	)
Interest and other income			7				25				225				49
Gain on sale of investments			-				-				7				-
Income before income taxes			1,174				1,210				2,468				2,580
Income tax expense			(295	)			(285	)			(513	)			(592	)
Net income		$	879			$	925			$	1,955			$	1,988
Basic net income per share:
Net income		$	0.25			$	0.25			$	0.54			$	0.54
Diluted net income per share:
Net income		$	0.24			$	0.25			$	0.53			$	0.53
Weighted average common shares outstanding:
Basic			3,574				3,657				3,595				3,654
Diluted			3,652				3,767				3,672				3,774
Common shares outstanding			3,554				3,642				3,554				3,642

Contact:

Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200

SOURCE: Pro-Dex, Inc.

View source version on accesswire.com:
https://www.accesswire.com/737760/Pro-Dex-Inc-Announces-Fiscal-2023-Second-Quarter-and-Six-Month-Results

FAQ

What were Pro-Dex's earnings for Q2 fiscal 2023?

Pro-Dex reported net income of $879,000 or $0.24 per diluted share for Q2 fiscal 2023.

How much did Pro-Dex's net sales increase in Q2 fiscal 2023?

Net sales increased by $1.1 million, or 11%, to $11.3 million.

What factors contributed to the decline in Pro-Dex's gross profit?

The decline in gross profit was primarily due to increased costs for components and higher repair expenses.

What is the future outlook for Pro-Dex following the Q2 earnings report?

Pro-Dex expects growth as operations at its new Franklin facility commence.